Among the 129 MDS patients, nine were identified as harboring a mutation in SF3B1 (7.0 %), 10 patients had mutations in U2AF1 (7.8 %), and 13 patients exhibited a mutation in SRSF2 (10.1 %). This evidence concerns the gene SRSF2 and myelodysplastic syndrome.